Smart Grid

TMCNet:  Research and Markets: The Pricing and Reimbursement Environment for Respiratory Disease Therapies

[January 10, 2013]

Research and Markets: The Pricing and Reimbursement Environment for Respiratory Disease Therapies

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/kg74wj/special_report) has announced the addition of Decision Resources, Inc's new report "Special Report: The Pricing and Reimbursement Environment for Respiratory Disease Therapies" to their offering.

Common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) make up a large and varied pharmaceutical market sector. These diseases also impose a significant burden on patients, providers, and payers, putting them front and center as the subjects of efforts to improve patient outcomes while containing costs to health systems. Governments and other payers are compelled to invest substantial resources in the management of these disorders. At the same time, payers continue to scrutinize the cost-to-benefit ratio o all therapeutic options very closely. The pharmaceutical industry will need to make a clear case for the role of drug therapy as a critical component in the effective management of respiratory disorders.

Story continues below ↓

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Healthcare system overviews: Healthcare sector reforms; roles of public and private payers; formulary decision makers.

Epidemiology: Prevalence of key respiratory diseases and drug-treatment rates in the seven major pharmaceutical markets in 2010 and 2020.

Pharmaceutical pricing: Procedures for setting prices; use of external reference pricing.

Admission to reimbursement: Bodies involved in reimbursement decision making; reimbursement procedures; reimbursement rates.

Cost containment: Reference pricing; prescribing restrictions; measures to promote greater use of generics.

Primary research: Results from a Web-based survey of 105 U.S. pulmonologists and primary care physicians (PCPs) who manage patients with respiratory diseases.

Outlook: Future pricing and reimbursement landscape for respiratory drug therapies.

Exhibits: 33 tables and figures showing comparative drug prices, respiratory disease epidemiology, market data, healthcare system characteristics, U.S. physician survey data, and payer coverage.

For more information visit http://www.researchandmarkets.com/research/kg74wj/special_report

Source (News - Alert): Decision Resources, Inc


[ Back To Smart Grid Home's Homepage ]




blog comments powered by Disqus